
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular ...
- Continued favorable safety profile for DYNE-251 - - DELIVER Registrational Expansion Cohort is fully enrolled; data from this cohort planned for late 2025 - - Potential for Biologics License Application submission for U.S. accelerated approval in early …